Logotype for Option Care Health Inc

Option Care Health (OPCH) Proxy filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Option Care Health Inc

Proxy filing summary

9 Nov, 2026

Executive summary

  • Merger agreement signed October 5, 2026; each eligible share converts to $32.05 cash, a ~42% premium to the October 2, 2026 closing price of $22.64.

  • CD&R-managed funds and McKesson are financing the ~$5.8 billion transaction; closing is expected in H1 2027, subject to stockholder and regulatory approvals.

  • If completed, the surviving corporation becomes a wholly owned subsidiary of Onyx Bidco; shares will be delisted from Nasdaq and deregistered under the Exchange Act.

Voting matters and shareholder proposals

  • December 15, 2026 virtual special meeting: vote on merger adoption, advisory merger-related executive compensation, and adjournment if needed for votes, quorum, or supplemental disclosures.

  • Board unanimously recommends FOR all three proposals; merger adoption requires affirmative votes from holders of a majority of outstanding shares entitled to vote.

  • Advisory compensation approval is non-binding and not a closing condition; contractual merger-related compensation remains payable if the deal closes, subject to applicable conditions.

  • As of the November 3, 2026 record date, 149,799,704 shares were entitled to vote; abstentions and non-votes have the same effect as AGAINST on merger adoption.

Board of directors and corporate governance

  • The board unanimously found the transaction fair, advisable, and in stockholders’ best interests after reviewing alternatives and negotiating terms; it directed submission of the merger agreement for a vote.

  • Sale process included outreach to 17 third parties and three non-binding bids; the board selected the $32.05 Investor Group offer, citing completed diligence, price, timing, and execution certainty.

  • Centerview’s October 5, 2026 opinion found the $32.05 consideration fair from a financial point of view; its DCF per-share range was $25.65–$34.05.

  • At closing, Merger Sub’s directors become directors of the surviving corporation; existing officers continue, subject to successors or earlier removal, resignation, or death.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Option Care Health